Non-Invasive Blood Glucose Monitoring System Market Size To Cross USD 129.75 Bn By 2030

The global non-invasive blood glucose monitoring system market size accounted for US$ 21.76 Bn in 2022 and is projected to reach around USD 129.75 Bn by 2030, growing at a CAGR of 25% from 2022 to 2030.

Report Summary

The global non-invasive blood glucose monitoring system market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the non-invasive blood glucose monitoring system market across the globe.

A comprehensive estimate on the non-invasive blood glucose monitoring system market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of non-invasive blood glucose monitoring system during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2405

Non-Invasive Blood Glucose Monitoring System Market Report Scope 

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized non-invasive blood glucose monitoring system market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read:  U.S. Corporate Wellness Market Size To Cross USD 34.27 Bn By 2030

Non-Invasive Blood Glucose Monitoring System Market Players

The report includes the profiles of key non-invasive blood glucose monitoring system market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

• Abbott Laboratories
• Medtronic plc
• F. Hoffmann-La Roche Ltd.
• Ascensia Diabetes Care
• Dexcom, Inc.
• Sanofi Novo Nordisk
• Insulet Corporation
• Ypsomed Holdings
• Glysens Incorporated

Market Segmentation

By Technology

• Spectroscopy
• Electromagnetic
• Microwave
• Ultrasonic
• Thermal
• Others

By End User

• Hospitals
• Homecare
• Clinics

By Modality

• Non wearable
• Wearable
• Invasive
• Non-invasive

By Distribution Channel

• Retail sales
• Institutional sales

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Regional Segmentation

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

• Governmental bodies, and organizations creating economic policies
• National and international social welfare institutions
• Company websites, financial reports and SEC filings, broker and investor reports
• Related patent and regulatory databases
• Statistical databases and market reports
• Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

• Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
• In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-Invasive Blood Glucose Monitoring System Market 

5.1. COVID-19 Landscape: Non-Invasive Blood Glucose Monitoring System Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-Invasive Blood Glucose Monitoring System Market, By Technology

8.1. Non-Invasive Blood Glucose Monitoring System Market, by Technology, 2022-2030

8.1.1. Spectroscopy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Electromagnetic

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Microwave

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Ultrasonic

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Thermal

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Non-Invasive Blood Glucose Monitoring System Market, By End User

9.1. Non-Invasive Blood Glucose Monitoring System Market, by End User, 2022-2030

9.1.1. Others

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Homecare

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Homecare

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Non-Invasive Blood Glucose Monitoring System Market, By Modality 

10.1. Non-Invasive Blood Glucose Monitoring System Market, by Modality, 2022-2030

10.1.1. Homecare

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Homecare

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Invasive

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Non-invasive

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Non-Invasive Blood Glucose Monitoring System Market, By Distribution Channel 

11.1. Non-Invasive Blood Glucose Monitoring System Market, by Distribution Channel, 2022-2030

11.1.1. Retail sales

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Institutional sales

11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Non-Invasive Blood Glucose Monitoring System Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Technology (2017-2030)

12.1.2. Market Revenue and Forecast, by End User (2017-2030)

12.1.3. Market Revenue and Forecast, by Modality (2017-2030)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.1.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.1.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.1.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.7.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.7.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Technology (2017-2030)

12.2.8.2. Market Revenue and Forecast, by End User (2017-2030)

12.2.8.3. Market Revenue and Forecast, by Modality (2017-2030)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.7.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.7.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Technology (2017-2030)

12.3.8.2. Market Revenue and Forecast, by End User (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Modality (2017-2030)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.7.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.7.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Technology (2017-2030)

12.4.8.2. Market Revenue and Forecast, by End User (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Modality (2017-2030)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Technology (2017-2030)

12.5.5.2. Market Revenue and Forecast, by End User (2017-2030)

12.5.5.3. Market Revenue and Forecast, by Modality (2017-2030)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Technology (2017-2030)

12.5.6.2. Market Revenue and Forecast, by End User (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Modality (2017-2030)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13. Company Profiles

13.1. Abbott Laboratories

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Medtronic plc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. F. Hoffmann-La Roche Ltd.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Ascensia Diabetes Care

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Dexcom, Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Sanofi Novo Nordisk

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Abbott

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Ypsomed Holdings

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Glysens Incorporated

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com